Discovery of Potent, Selective and Efficacious Aminopyrazole Inhibitors of PLK4

Polo-like kinase 4 (PLK4) is a therapeutic target of high interest due to its essential role in mitotic regulation and centriole duplication. Recently, centriole depletion driven by PLK4 inhibition has been identified as a synthetically lethal target for cancers with elevated TRIM37 expression. Herein, we disclose the discovery of <b>25</b>, a potent and selective PLK4 inhibitor. A validated hit from high-throughput screening of our compound library provided the starting point for further optimization. Structural analysis of multiple X-ray cocrystal structures enabled the design of analogs that demonstrated excellent kinome selectivity. Tumor regression was observed in efficacy studies of compound <b>25</b> in a CHP-134 neuroblastoma xenograft tumor model.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-12-02
DOI
https://doi.org/10.1021/acs.jmedchem.5c02200
Primary Topic
Microtubule and mitosis dynamics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Potent, Selective and Efficacious Aminopyrazole Inhibitors of PLK4

Jae Hoon Chang, Dana M. Gwinn, Trevor Chang, Brian Sherer et al.
Journal of Medicinal Chemistry
Microtubule and mitosis dynamics
article

Discovery of Potent, Selective and Efficacious Aminopyrazole Inhibitors of PLK4

Jae Hoon Chang, Dana M. Gwinn, Trevor Chang, Brian Sherer, André H. St. Amant, Jeremy M. Murray, Sanjay Bhattarai, Christopher J. Kochansky, Ryan L. Gonciarz, Justin M. Salvant, Leo Mok, Ziqiang Wang, Jo-Ting Chang, Heather J. Finlay, Nina M. Muñoz, Rieko Matsuura, Wei Xu, Kai S. Yang, Joon Won Jeong, David Shaya, Andrew G. Raub
article en

Abstract

Polo-like kinase 4 (PLK4) is a therapeutic target of high interest due to its essential role in mitotic regulation and centriole duplication. Recently, centriole depletion driven by PLK4 inhibition has been identified as a synthetically lethal target for cancers with elevated TRIM37 expression. Herein, we disclose the discovery of <b>25</b>, a potent and selective PLK4 inhibitor. A validated hit from high-throughput screening of our compound library provided the starting point for further optimization. Structural analysis of multiple X-ray cocrystal structures enabled the design of analogs that demonstrated excellent kinome selectivity. Tumor regression was observed in efficacy studies of compound <b>25</b> in a CHP-134 neuroblastoma xenograft tumor model.

Journal of Medicinal ChemistryVol. 68(23)
Exelixis (United States) (US)
Openalex Percentile: Top 60%
Microtubule and mitosis dynamics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.